NASDAQ:ALNY', 'Alnylam Pharmaceuticals Inc.', 'http://weeklyregister.com/weekly-register-logo.png');

A Reversal for Alnylam Pharmaceuticals, Inc. (ALNY) Is Near. The Formed Double Top Chart Pattern

December 7, 2017 - By Vivian Park

Investors sentiment increased to 1.52 in Q2 2017. Its up 0.70, from 0.82 in 2017Q1. It is positive, as 24 investors sold Alnylam Pharmaceuticals, Inc. shares while 49 reduced holdings. 49 funds opened positions while 62 raised stakes. 85.40 million shares or 6.40% more from 80.26 million shares in 2017Q1 were reported.
Morgan Stanley accumulated 1.02 million shares or 0.02% of the stock. Balyasny Asset Mngmt Limited Liability Com invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Geode Cap Mgmt Limited Liability Corporation, a Massachusetts-based fund reported 662,405 shares. Evercore Wealth Ltd accumulated 600 shares. Td Asset Incorporated invested in 129,918 shares or 0.02% of the stock. Neuberger Berman Limited Company holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 2,873 shares. Aperio reported 0.01% stake. Proshare Ltd Limited Liability Company invested in 48,505 shares or 0.04% of the stock. State Street Corporation invested in 0.01% or 1.94M shares. Commonwealth Equity has invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 175 were reported by Bessemer Gru Incorporated. Great Point Ltd Liability stated it has 276,800 shares or 3.96% of all its holdings. Pioneer Inv Inc reported 0.04% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Gam Holding Ag has 10,000 shares for 0.01% of their portfolio. Benjamin F Edwards & has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

The chart of Alnylam Pharmaceuticals, Inc. (ALNY) shows a double top with $139.03 target or 8.00 % above today’s $128.73 share price. The 5 months chart pattern indicates low risk for the $12.77B company. It was reported on Dec, 7 by Finviz.com. If the $139.03 price target is reached, the company will be worth $1.02B more. Double tops are rare but powerful chart patterns.

The stock increased 3.34% or $4.16 during the last trading session, reaching $128.73. About 754,726 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since December 7, 2016 and is uptrending. It has outperformed by 16.84% the S&P500.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on February, 14. They expect $-1.36 earnings per share, down 3.03 % or $0.04 from last year’s $-1.32 per share. After $-1.34 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 1.49 % negative EPS growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 84 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Outperform” rating by BMO Capital Markets on Friday, September 22. As per Friday, November 3, the company rating was maintained by Needham. The company was maintained on Wednesday, September 20 by Piper Jaffray. JMP Securities maintained it with “Market Outperform” rating and $135 target in Wednesday, March 9 report. The firm earned “Overweight” rating on Wednesday, November 8 by Barclays Capital. JP Morgan upgraded the shares of ALNY in report on Thursday, November 9 to “Overweight” rating. The firm has “Buy” rating by Needham given on Thursday, October 6. The rating was maintained by Needham with “Buy” on Thursday, September 21. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Outperform” rating by FBR Capital on Thursday, October 6. JP Morgan upgraded the shares of ALNY in report on Friday, March 11 to “Overweight” rating.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Alnylam Pharmaceuticals, Inc.’s Pipeline Progresses, Approval Next” on November 15, 2017, also Businesswire.com with their article: “Alnylam Pharmaceuticals Announces Proposed Public Offering of $675000000 of …” published on November 13, 2017, Seekingalpha.com published: “Alnylam Sets Its Eyes On The Finish Line” on November 20, 2017. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Fool.com and their article: “Why Alnylam Pharmaceuticals Rose 12.7% in November” published on December 06, 2017 as well as Businesswire.com‘s news article titled: “Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock …” with publication date: November 16, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.